Hope Medical Enterprises, Inc. v. Fagron Compounding Services, LLC
Opinion
trial_court Opinion
I. INTRODUCTION AND BACKGROUND
Plaintiff Hope Medical Enterprises, Inc., d/b/a/ Hope Pharmaceuticals (“Hope”) filed this action against defendants Fagron Compounding Services, LLC (“Fagron’’), JCB Laboratories, LLC (“JCB”), AnazaoHealth Corporation (“AnazaoHealth”), and Coast Quality Pharmacy, LLC (“Coast”) (collectively, “defendants’’) on September 6, 2019. Dkt. 1. Hope filed its operative first amended complaint on November 12, 2019. Dkt. 47 (“FAC”). The FAC asserts claims for: (1) violation of California’s Unfair Competition Law (“UCL”): (2) violation of Florida’s Deceptive and Unfair Trade Practices Act (“FDUTPA”):; (3) violation of the Tennessee’s Consumer Protection Act (““TCPA”): (4) violation of South Carolina’s Unfair Trade Practices Act (“SCUTPA”); and (5) violation of Connecticut’s Unfair Trade Practices Act (“CUTPA”). Id. Hope is a pharmaceutical company which markets and sells Sodium Thiosfulfate Injection and Sodium Nitrite Injection. FAC § 26. Hope sells its Sodium Thiosulfate Injection to medical facilities and other customers located in states including California,